RE:Proph says...."The merger with AEZS arguably values.....AEZS's diagnostic test was to complete pediatric trial enrollement in December 2023. The pediatric clinical trial data, expected regulatory approval this year, and a new North American licensing deal should drive AEZS towards H.C. Wainwright's US$15 target. Gilles is on the Board of Directors of AEZS and should have a very good idea concerning the deal expected to be signed. The test is already approved for the adult market helping to limit risk for pediatric approval. AZES also appears to be nearing a 'go' decision concerning clinical trials for a pipeline asset(s). The value of the previous Strongbridge and Novo Nordisk agreements for AEZS's diagnostic test are very supportive of H.C. Wainwright's target valuation. The size of the growth hormone deficiency testing market is also well known and AEZS has the only dedicated test so a valuation is relatively objective. It is already being used in adults and so the benefits of the test can be seen. The childhood market is the most important for growth hormone deficiency.
US$15 for AEZS works out to C$100 million market cap. As a merger of equals should it be surprising that CZO could be so valued? That CZO could be worth C$100 million shouldn't be surprising. CZO's main client is expected to return. CZO's growth is expected at historic trends after the 2023 adjustment year according to Gilles in his October presentation. New powder products are expected to be launched with Symrise opening up new markets. The avenanthramide malted technology is also at commercial scale.
Carolyn Egbert, Chair of Aeterna also stated in the news release: “Ceapro has well-established and growing commercial operations..." CZO's market cap has been as high as C$56 million in the last year. Using that as a go forward valuation that means only $44 million is needed for the pipeline to reach the C$100 million target. The net present value of the immune booster plant alone was $100 million previously according to Gilles. The merger with AEZS provides capital to move forward and tax loss carryforwards. GIlles also notified shareholders at the AGM that it is in talks with serious companies concerning a PGX deal in the $4 billion CoQ10 market. That Gilles has moved ahead with the 100L PGX scale-up with Natex as the 50L scale-up is being completed and that Gilles wants to move to NASDAQ now speaks to the confidence CZO has in the PGX scale-up. AEZS has also agreed to the merger at this point in PGX's scale-up. We seem well on the way to PGX at commercial scale and a deal. Natex already had 50% of the equipment and infrastructure in place as of the November release foe 100L scale-up.
Avalyn Pharma raised C$80 million going into its Phase I and CZO's fibrosis drug could profoundly change the fibrosis treatment landscape according to Dr. Kolb who was involved with Avanyn's drug. CZO also has the avenanthramide pill clinical trial which continues as planned with no adverse events as noted in a news release. There is also the wound healng opportunity and more. That CZO is could be worth much more than C$100 million appears quite possible. This suggests H.C. Wainwright's US$15(C$100 million market cap) target for AEZS may be too conservative.
There is a lot going on. Ronnie Miller is "thrilled" coming from the largest biotech company in the world. Gilles is in the catbird seat at CZO and AEZS and is 'excited'. He wants CZO's story on NASDAQ. The Chair of AEZS is 'compelled'. Minty_33 wrote: CZO's shares at $1.25 given H.C. Wainwright's US$15 target price for AEZS".
AND the current share price is $1.98 so CZO stock is essentially getting cut in half. FUTHERMORE H.C Wainwright are notorious for dumping their stock on shareholders. They have a 1.8 stars out of 5 on Google Reviews. Would you go to a restaurant or a weeks vacation at a resort with those ratings? So why would anyone believe these clowns?
Garbage Company and beqare of bs pumpers like used prophylactic